Pharmakotherapie - Physostigmin post OP

 

 Buy Article Permissions and Reprints

Zusammenfassung

Physostigmin, ein reversibler Acteylcholinesterasehemmer, ist Mittel der Wahl in der Therapie postoperativer Vigilanzstörungen. Sie entstehen durch Blockade zentral cholinerger Neurone und/oder Acetylcholinmangel und werden unter dem Begriff Zentral-Anticholinerges Syndrom zusammengefasst. Physostigmin findet seinen Einsatz ebenfalls in der Therapie des postoperativen shiverings, bei Intoxikationen, in der antideliranten Therapie und in der Schmerztherapie.

Abstract

The central anticholinergic syndrome should be considered in patients with altered mental status following anaesthesia. Physostigmine, a reversible acetylcholinesterase inhibitor, is a first-line medicament for the therapy of the central anticholinergic syndrome. Physostigmine crosses the blood-brain barrier and elevates acetylcholine levels in the brain. For prevention of postanaesthetic shivering, for treatment of intoxications and postoperative pain, and for patients suspected of having antimuscarinic delirium physostigmin is also indicated.

Literatur

• 1 Anticholium® ,Gebrauchsinformation. Dr. Franz Köhler Chemie GmbH
  Google Scholar
• 2 Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds.  Pharmacol Rev. 1966;  18 965-996
  PubMedGoogle Scholar
• 3 Link J, Papadopoulos G, Dopjans D, Guggenmoos-Holzmann I, Eyrich K. Distinct central anticholinergic syndrome following general anesthesia.  Eur J Anaesthesiol. 1997;  14 15-23
  CrossrefPubMedGoogle Scholar
• 4 Rupreth J, Dworacek B. The central anticholinergic syndrome in the postoperative period.  In: Nunn JF, Utting JE, Brown BR eds. General Anaesthesia 5th Edn.  London: Butterworth. 1989;  1141-1148
  PubMedGoogle Scholar
• 5 Rupreth J, Dworacek B. Central anticholinergic syndrome during postoperative period.  Ann Fr Anesth Reanim. 1990;  9 295-304
  PubMedGoogle Scholar
• 6 Senne I, Zourelidis C, Irnich D, Kurz M, Hummel T, Zwissler B. Rezidivierende Bewusstlosigkeit und Atemstillstand nach Allgemeinanästhesie.  Anaesthesist. 2003;  52 608-611
  CrossrefPubMedGoogle Scholar
• 7 Hall RCW, Fox J, Stickney SK. Anticholinergic delirium: etiology, presentation, diagnosis and management.  J Psychoactive Drugs. 1978;  10 237-241
  PubMedGoogle Scholar
• 8 Brown DV, Heller F, Barkin R. Anticholinergic syndrome after anesthesia: a case report and review.  AM J Ther. 2004;  11 144-153
  CrossrefPubMedGoogle Scholar
• 9 Ries NL, Dart RC. New Developments in Antidotes.  Med Clin N Am. 2005;  89 1379-1397
  CrossrefPubMedGoogle Scholar
• 10 Horn EP, Standl T, Sessler DI, Knobelsdorff G von, Buchs C, Schulte J am Esch. Physostigmin e prevents postanaesthetic shivering as does meperidine or clonidine.  Anesthesiology. 1998;  88 108-113
  PubMedGoogle Scholar
• 11 Röhm KD, Riechmann J, Boldt J, Schuler S, Suttner SW, Piper SN. Physostigmin e for the prevention of postanaesthetic shivering following general anaesthesia- a placebo-controlled comparison with nefopam.  Anaesthesia. 2005;  60 433-438
  CrossrefPubMedGoogle Scholar
• 12 Beilin B, Bessler H, Papismedov L, Weinstock M, Shavit Y. Continuous Physostigmin e combined with morphine-based-patient-controlled analgesia in the postoperative period.  Acta Anaesthesiol. Scand. 2005;  49 78-84
  CrossrefPubMedGoogle Scholar
• 13 Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, Clark RF. Complications of diagnostic Physostigmin e administration to emergency department patients.  Annals of Emergency Medicine. 2003;  42 14-19
  CrossrefPubMedGoogle Scholar

Dr. med. Ulrike Haase

Email: ulrike.haase@charite.de

PD Dr. med. Ingrid Rundshagen

Email: ingrid.rundshagen@charite.de